Morbilliform drug reaction with histologic features of pustular dermatosis associated with bryostatin-1
Krejci-Manwaring, J.M.; Bogle, M.A.; Diwan, H.A.; Duvic, M.A.
Journal of Drugs in Dermatology Jdd 2(5): 557-561
2003
ISSN/ISBN: 1545-9616 PMID: 14558406 Document Number: 9389
Bryostatin-1 is a new chemotherapeutic agent that inhibits protein kinase C. The most common side effect and the dose limiting toxicity is myalgia. The cutaneous side effects reported during the phase I and II trials were alopecia, mucositis, nonspecific "rash," "bronzing," and hyperpigmentation in sun exposed areas. No specific acute drug eruptions have been reported. We present the first reported case of a morbilliform drug eruption with histologic features of intraepidermal and subcorneal spongiotic pustules containing eosinophils secondary to bryostatin-1.
Document emailed within 1 workday
